Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients

Journal of the Formosan Medical Association

Volumn 115, Issue 6, 2016, Pages 411-417

  Pan, Hsiang Ju ^a   Chang, Hong Tai ^a   Lee, Chien Hung ^b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Hormonal therapy; Nonalcoholic fatty liver; Tamoxifen

Indexed keywords

TAMOXIFEN; ANTIESTROGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PREVALENCE; ULTRASOUND; ABDOMEN; BLOOD EXAMINATION; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; LIFESTYLE; MIDDLE AGED; PATHOLOGY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

ABDOMEN; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HEMATOLOGIC TESTS; HUMANS; LIFE STYLE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS; TAIWAN; TAMOXIFEN; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 84930714905     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2015.05.006     Document Type: Article

References (28)

1. Health Promotion Administration, Ministry of Health and Welfare, Cancer Prevention and Control. at . [accessed 30.12.14]. http://www.hpa.gov.tw/BHPNet/Web/Healthtopic/TopicBulletin.aspx?No=201009170001%26parentid=200712250030.
2. 2012 Taiwan public health report at . [accessed 30.12.14]. http://open.nat.gov.tw/OpenFront/gpnet_detail.jspx?gpn=2008800168.
3. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Medicine 1998, 339:1609-1618.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
5. Akhondi-Meybodi M., Mortazavy-Zadah M.R., Hashemian Z., Moaiedi M. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab J Gastroenterol 2011, 12:34-36.
6. Ashraf M., Biswas J., Majumdar S., Nayak S., Alam N., Mukherjee K.K., et al. Tamoxifen use in Indian women-adverse effects revisited. Asian Pac J Cancer Prev 2009, 10:609-612.
7. Liu C.L., Huang J.K., Cheng S.P., Chang Y.C., Lee J.J., Liu T.P. Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs 2006, 17:709-713.
8. Ogawa Y., Murata Y., Nishioka A., Inomata T., Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998, 351:725.
9. Hsu C.S., Kao J.H. Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan. J Formos Med Assoc 2012, 111:527-535.
10. Baumeister S.E., Volzke H., Marschall P., John U., Schmidt C.O., Flessa S., et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008, 134:85-94.
11. Lazo M., Hernaez R., Eberhardt M.S., Bonekamp S., Kamel I., Guallar E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013, 178:38-45.
12. Lanaspa M.A., Sanchez-Lozada L.G., Cicerchi C., Li N., Roncal-Jimenez C.A., Ishimoto T., et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PloS One 2012, 7:e47948.
13. Pagadala M.R., McCullough A.J. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis 2012, 16:487-504.
14. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
15. Schwenzer N.F., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51:433-445.
16. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
17. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
18. Haskell W.L., Lee I.M., Pate R.R., Powell K.E., Blair S.N., Franklin B.A., et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007, 39:1423-1434.
19. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
20. Hadji P., Ziller V., Kyvernitakis J., Bauer M., Haas G., Schmidt N., et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: A retrospective database analysis. Breast Cancer Res Treat 2013, 138:185-191.
21. Nemoto Y., Saibara T., Ogawa Y., Zhang T., Xu N., Ono M., et al. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med 2002, 41:345-350.
22. Patel V., Sanyal A.J. Drug-induced steatohepatitis. Clin Liver Dis 2013, 17:533-546.
23. Begriche K., Massart J., Robin M.-A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011, 54:773-794.
24. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2009, 103:71-83.
25. Yang T.L., Wu T.C., Huang C.C., Huang P.H., Chung C.M., Lin S.J., et al. Association of tamoxifen use and reduced cardiovascular events among asian females with breast cancer. Circ J 2013, 78:135-140.
26. Armstrong M.J., Houlihan D.D., Bentham L., Shaw J.C., Cramb R., Olliff S., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012, 56:234-240.
27. Festi D., Schiumerini R., Marzi L., Di Biase A.R., Mandolesi D., Montrone L., et al. Review article: the diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013, 37:392-400.
28. Hernaez R., Lazo M., Bonekamp S., Kamel I., Brancati F.L., Guallar E., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011, 54:1082-1090.